Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rivaroxaban-Stroke'

Rivaroxaban-Stroke published presentations and documents on DocSlides.

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
by giovanna-bartolotta
Rivaroxaban Plus Aspirin in Patients With and Wit...
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
by yoshiko-marsland
(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....
Rivaroxaban compared with enoxaparin for the prevention of
Rivaroxaban compared with enoxaparin for the prevention of
by luanne-stotts
Alexander T Cohen . On behalf of the MAGELLAN Ste...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by alexa-scheidler
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Stroke, Bleeding, and
Stroke, Bleeding, and
by lois-ondreau
Mortality Risks . in . Elderly Medicare Beneficia...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by debby-jeon
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
by LittleMissPerfect
rivaroxaban. group vs. 1.02% of the vitamin K ant...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by coursion
R. ivaroxaban . I. n atrial . F. ibrillation patie...
Ima A. Kusuma , MD, FIHA
Ima A. Kusuma , MD, FIHA
by hirook
“JIH. ” Hospital, Yogyakarta, Indonesia. The U...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by stefany-barnette
A ssessment of D ual antiplatelet therapy versus...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
R eal-world
R eal-world
by liane-varnes
EVI. dence. on . S. troke prevention . I. n pati...
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
by kyle585
Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....
Review on NOACs Studies Dr.
Review on NOACs Studies Dr.
by BlessedBeyondMeasure
Kourosh. . Sadeghi. Tehran University of medical ...
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
by HoneyBun
VTE death. ) for . rivaroxaban. vs. . enoxaparin....
Thromboembolic protocols
Thromboembolic protocols
by cecilia
& safe anticoagulant prescribing. July 2020. D...
Rivaroxaban in stable peripheral or carotid artery disease
Rivaroxaban in stable peripheral or carotid artery disease
by basidell
Sonia Anand, on . behalf of the COMPASS Steering C...
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
by yoshiko-marsland
Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
New Oral Anticoagulant
New Oral Anticoagulant
by mitsue-stanley
R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Novel Oral Anticoagulants
Novel Oral Anticoagulants
by natalia-silvester
(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...
Recent ACS: STEMI, NSTEMI, UA
Recent ACS: STEMI, NSTEMI, UA
by danika-pritchard
Stabilized 1-7 Days Post-Index Event. Exclusions:...
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
by dorothy
Mpiko. . Ntsekhe. , Bongani . Mayosi. * and Salim...
COMPASS: Show Us the Way for Medical Management of PAD
COMPASS: Show Us the Way for Medical Management of PAD
by miller
Clinical Associate Professor of Medicine. SSM Heal...
Neurobehavioural consequences of stroke – Overview of stroke
Neurobehavioural consequences of stroke – Overview of stroke
by ozzy
Stroke throughout history. CT=computerized tomogra...
Stroke Association – New Era for Stroke
Stroke Association – New Era for Stroke
by mustafa296
AMEC International Communication Effectiveness Awa...
Neurobehavioural consequences of stroke – Post-stroke NPS
Neurobehavioural consequences of stroke – Post-stroke NPS
by cole755
Prevalence of post-stroke fatigue. Post-stroke fat...
Stroke by the numbers South Carolina Stroke RACE
Stroke by the numbers South Carolina Stroke RACE
by della
R. apid . A. rterial . o. C. clusion. . E. valuat...
Stroke and dysphagia stroke
Stroke and dysphagia stroke
by eloise
There are two types of strokes . –. . ischaemic...
Stroke Stroke Second important cause of death
Stroke Stroke Second important cause of death
by ash
Physical and pshychosocial handicap. Lesions of br...
Surviving Stroke What You Need to Know About Stroke and Long-term Disability
Surviving Stroke What You Need to Know About Stroke and Long-term Disability
by luanne-stotts
National Stroke Association. ADVOCATE. – Influ...
Surviving Stroke What You Need to Know About Stroke and Long-term Disability
Surviving Stroke What You Need to Know About Stroke and Long-term Disability
by conchita-marotz
National Stroke Association. ADVOCATE. – Inf...
Atypical Stroke Presentation: The Art and Science of Stroke
Atypical Stroke Presentation: The Art and Science of Stroke
by alexa-scheidler
Sarah L. Livesay, DNP, RN, ACNP-BC. Assistant Pro...
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
by dsuser1
Christopher Granger, . MD. Sean Pokorney, MD. . D...
Pharmaceutical Management of Cardiac Medications:
Pharmaceutical Management of Cardiac Medications:
by pamella-moone
A Look at New Oral Anticoagulants. Linda Wing, . ...
Dodson Thompson, DO
Dodson Thompson, DO
by lois-ondreau
Northlakes. Community Clinic. Minong, WI. Novel ...
Oral anticoagulants in the 21
Oral anticoagulants in the 21
by natalia-silvester
st. century: A practical guide to using newer A...
Management of
Management of
by marina-yarberry
Atrial. Fibrillation. Phillip H. Lam, M.D.. Chie...